{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:52:25Z","timestamp":1789883545423,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Boehringer Ingelheim PCV2 award (2009)"},{"name":"Conseil D\u00e9partemental des C\u00f4tes d\u2019Armor"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.06.005","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T07:15:32Z","timestamp":1467011732000},"page":"3738-3745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A commercial PCV2a-based vaccine significantly reduces PCV2b transmission in experimental conditions"],"prefix":"10.1016","volume":"34","author":[{"given":"N.","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Andraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jestin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Grasland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.06.005_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.prevetmed.2003.07.003","article-title":"Risk factors for porcine post-weaning multisystemic wasting syndrome (PMWS) in 149 French farrow-to-finish herds","volume":"61","author":"Rose","year":"2003","journal-title":"Prev Vet Med"},{"key":"10.1016\/j.vaccine.2016.06.005_b0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.prevetmed.2004.11.015","article-title":"An exploratory study on risk factors for postweaning multisystemic wasting syndrome (PMWS) in Spain","volume":"69","author":"Lopez-Soria","year":"2005","journal-title":"Prev Vet Med"},{"key":"10.1016\/j.vaccine.2016.06.005_b0015","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/vr.160.22.751","article-title":"Spatiotemporal patterns and risks of herd breakdowns in pigs with postweaning multisystemic wasting syndrome","volume":"160","author":"Woodbine","year":"2007","journal-title":"Vet Rec"},{"key":"10.1016\/j.vaccine.2016.06.005_b0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.prevetmed.2009.07.009","article-title":"Influence of husbandry and control measures on porcine circovirus type 2 (PCV-2) dynamics within a farrow-to-finish pig farm: a modelling approach","volume":"92","author":"Andraud","year":"2009","journal-title":"Prev Vet Med"},{"key":"10.1016\/j.vaccine.2016.06.005_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/1297-9716-45-13","article-title":"Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge","volume":"45","author":"Seo","year":"2014","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2016.06.005_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cimid.2009.09.006","article-title":"Efficacy of different protocols of vaccination against porcine circovirus type 2 (PCV2) in a farm affected by postweaning multisystemic wasting syndrome (PMWS)","volume":"33","author":"Pejsak","year":"2010","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.005_b0035","first-page":"737","article-title":"Efficacy of immunising pigs against porcine circovirus type 2 at three or six weeks of age","volume":"163","author":"Cline","year":"2008","journal-title":"Vet Rec"},{"key":"10.1016\/j.vaccine.2016.06.005_b0040","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2460\/javma.232.6.906","article-title":"A field evaluation of mortality rate and growth performance in pigs vaccinated against porcine circovirus type 2","volume":"232","author":"Horlen","year":"2008","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2016.06.005_b0045","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.vaccine.2008.04.032","article-title":"Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2","volume":"26","author":"Kixmoller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.005_b0050","first-page":"148","article-title":"Use of a one-dose subunit vaccine to prevent losses associated with porcine circovirus type 2","volume":"17","author":"Desrosiers","year":"2009","journal-title":"J Sw Health Prod"},{"key":"10.1016\/j.vaccine.2016.06.005_b0055","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1016\/j.vaccine.2009.09.084","article-title":"A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms","volume":"27","author":"Segal\u00e9s","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.005_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.vetimm.2008.12.024","article-title":"Development of cell-mediated immunity to porcine circovirus type 2 (PCV2) in caesarean-derived, colostrum-deprived piglets","volume":"129","author":"Fort","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2016.06.005_b0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.vetimm.2012.09.001","article-title":"Evaluation of cell-mediated immune responses against porcine circovirus type 2 (PCV2) Cap and Rep proteins after vaccination with a commercial PCV2 sub-unit vaccine","volume":"150","author":"Fort","year":"2012","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2016.06.005_b0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/vr.163.18.536","article-title":"Lack of transmission of porcine circovirus type 2 to weanling pigs by feeding them spray-dried porcine plasma","volume":"163","author":"Pujols","year":"2008","journal-title":"Vet Rec"},{"key":"10.1016\/j.vaccine.2016.06.005_b0075","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.tvjl.2013.05.043","article-title":"Effectiveness of porcine circovirus type 2 vaccination in reducing the severity of post-weaning multisystemic wasting syndrome in pigs","volume":"197","author":"Velasova","year":"2013","journal-title":"Veterinary J"},{"key":"10.1016\/j.vaccine.2016.06.005_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trivac.2013.02.001","article-title":"Efficacy of vaccination of 3-week-old piglets with Circovac\u00ae against porcine circovirus diseases (PCVD)","volume":"2","author":"Hei\u00dfenberger","year":"2013","journal-title":"Trials Vaccinol"},{"key":"10.1016\/j.vaccine.2016.06.005_b0085","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1016\/j.vaccine.2014.06.004","article-title":"Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2","volume":"32","author":"Opriessnig","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.005_b0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1586\/14760584.2015.983084","article-title":"Best practice and future challenges for vaccination against porcine circovirus type 2","volume":"14","author":"Segal\u00e9s","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.06.005_b0095","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.vaccine.2007.11.053","article-title":"The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex","volume":"26","author":"Fachinger","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.005_b0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.vetmic.2012.07.021","article-title":"Effect of sow and piglet porcine circovirus type 2 (PCV2) vaccination on piglet mortality, viraemia, antibody titre and production parameters","volume":"161","author":"Fraile","year":"2012","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.005_b0105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.prevetmed.2010.11.015","article-title":"A meta-analysis comparing the effect of PCV2 vaccines on average daily weight gain and mortality rate in pigs from weaning to slaughter","volume":"98","author":"Kristensen","year":"2011","journal-title":"Prev Vet Med"},{"key":"10.1016\/j.vaccine.2016.06.005_b0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1098\/rsif.2008.0210","article-title":"Modelling the time-dependent transmission rate for porcine circovirus type 2 (PCV2) in pigs using data from serial transmission experiments","volume":"6","author":"Andraud","year":"2009","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.vaccine.2016.06.005_b0115","doi-asserted-by":"crossref","DOI":"10.1051\/vetres:2008020","article-title":"Quantification of porcine circovirus type 2 (PCV-2) within- and between-pen transmission in pigs","volume":"39","author":"Andraud","year":"2008","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2016.06.005_b0120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1051\/vetres:2005024","article-title":"Reproduction of PMWS in immunostimulated SPF piglets transfected with infectious cloned genomic DNA of type 2 porcine circovirus","volume":"36","author":"Grasland","year":"2005","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2016.06.005_b0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-1135(03)00131-7","article-title":"An ORF2 protein-based ELISA for porcine circovirus type 2 (PCV2) antibodies in post-weaning multisystemic wasting syndrome (PMWS)","volume":"94","author":"Blanchard","year":"2003","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.005_b0130","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.vaccine.2015.03.040","article-title":"Porcine reproductive and respiratory syndrome virus (PRRSv) modified-live vaccine reduces virus transmission in experimental conditions","volume":"33","author":"Rose","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.005_b0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"R: a language for data analysis and graphics","volume":"5","author":"Ihaka","year":"1996","journal-title":"J Comput Graph Stat"},{"key":"10.1016\/j.vaccine.2016.06.005_b0140","series-title":"SAS\/STAT User\u2019s Guide","author":"SAS Institute Inc","year":"2011"},{"key":"10.1016\/j.vaccine.2016.06.005_b0145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.vetmic.2012.01.024","article-title":"Vaccination with inactivated or live-attenuated chimeric PCV1-2 results in decreased viremia in challenge-exposed pigs and may reduce transmission of PCV2","volume":"158","author":"Hemann","year":"2012","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.005_b0150","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0264-410X(94)90229-1","article-title":"Experimental quantification of vaccine-induced reduction in virus transmission","volume":"12","author":"De Jong","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.005_b0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0167-5877(03)00082-5","article-title":"Design and analysis of an Actinobacillus pleuropneumoniae transmission experiment","volume":"60","author":"Velthuis","year":"2003","journal-title":"Prev Vet Med"},{"key":"10.1016\/j.vaccine.2016.06.005_b0160","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S0950268801006707","article-title":"Quantification of transmission in one-to-one experiments","volume":"128","author":"Velthuis","year":"2002","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.06.005_b0165","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1016\/S0264-410X(01)00099-8","article-title":"A quantitative assessment of the effectiveness of PRRSV vaccination in pigs under experimental conditions","volume":"19","author":"Nodelijk","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.005_b0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.vetmic.2014.11.007","article-title":"Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model","volume":"175","author":"Pileri","year":"2015","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.005_b0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.rvsc.2014.04.007","article-title":"Comparative analyses of humoral and cell-mediated immune responses upon vaccination with different commercially available single-dose porcine circovirus type 2 vaccines","volume":"97","author":"Seo","year":"2014","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.vaccine.2016.06.005_b0180","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1016\/j.vaccine.2009.04.028","article-title":"One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model","volume":"27","author":"Fort","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T22:46:48Z","timestamp":1718664408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16304042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":36,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16304042"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A commercial PCV2a-based vaccine significantly reduces PCV2b transmission in experimental conditions","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}